Trial Profile
A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 01 Nov 2019 Primary endpoint (Phase 2: Progression Free Survival at 6 months) has been met according to Results published in the Clinical Cancer Research
- 01 Nov 2019 Primary endpoint (Phase 2: Objective Response Rate) has been met according to Results published in the Clinical Cancer Research
- 01 Nov 2019 Results published in the Clinical Cancer Research